Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-08-071304
Filing Date
2008-03-31
Accepted
2008-03-31 17:07:45
Documents
7
Period of Report
2007-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-K d10ka.htm 10-K/A 846947
2 LIST OF SUBSIDIARIES dex21.htm EX-21 2917
3 CONSENT OF ODENBERG, ULLAKKO, MURANISHI & CO. LLP dex231.htm EX-23.1 2077
4 CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) AND RULE 15D-14(A) dex311.htm EX-31.1 9311
5 CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) AND RULE 15D-14(A) dex312.htm EX-31.2 9362
6 CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. 1350 dex32.htm EX-32 4835
7 GRAPHIC g93863g84c28.jpg GRAPHIC 56132
  Complete submission text file 0001193125-08-071304.txt   954401
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 4152444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-13341 | Film No.: 08725870
SIC: 2836 Biological Products, (No Diagnostic Substances)